| Current Price | $1.81 | Mkt Cap | $586.8M |
|---|---|---|---|
| Open | $1.89 | P/E Ratio | 0.00 |
| Prev. Close | $1.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.80 - $1.91 | Volume | 4,459,834 |
| 52-Wk Range | $0.75 - $2.40 | Avg. Daily Vol. | 4,032,267 |
A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.
| Current Price | $1.81 | Mkt Cap | $586.8M |
|---|---|---|---|
| Open | $1.89 | P/E Ratio | 0.00 |
| Prev. Close | $1.81 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $1.80 - $1.91 | Volume | 4,459,834 |
| 52-Wk Range | $0.75 - $2.40 | Avg. Daily Vol. | 4,032,267 |
The best Bull and Bear pitches based on recency and number of recommendations.
This company has found an effective cancer treatment that has only a relatively small, easily managed toxicity. It is on the frontier of not only being a potential stand alone agent, but also may improve other cancer agents when used in combination.… More
Embryonic stem cell research, regardless of the current presidential/congressional support, is in trouble. They have not figured out how to fix the problems (e.g. cancerous tumors), yet "adult" stem cells (e.g., from dental pulp, bone marrow, and… More
Read the most recent pitches from players about GERN.
Recs
KingGoat
(< 20)
Submitted: 2/20/2021 12:38:50 PM :
Start Price:
$1.94
NASDAQ:GERN Score:
-6.37
Phase 3 study in progress.
Recs
LastPlaceLenny
(67.25)
Submitted: 3/15/2019 2:46:17 AM :
Start Price:
$1.66
NASDAQ:GERN Score:
+27.25
Still waiting for my stocks to go to zero. Lost so much, no point cashing out now....
Recs
streetdan
(< 20)
Submitted: 9/9/2018 10:31:50 AM :
Start Price:
$6.15
NASDAQ:GERN Score:
-102.98
This company has found an effective cancer treatment that has only a relatively small, easily managed toxicity. It is on the frontier of not only being a potential stand alone agent, but also may improve other cancer agents when used in combination. They have therefore an agent that can disrupt cancers progression without significant harm to normal cells.
Find the members with the highest scoring picks in GERN.
SheepInvstr213 (< 20) Score: +563.74
The Score Leader is the player with the highest score across all their picks in GERN.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| SheepInvstr213 | < 20 | 3/9/2009 |
|
5Y | $4.59 | -60.58% | +468.98% | +529.57 | 0 Comment | |
| epc53 | 26.92 | 3/3/2009 |
|
NS | $3.85 | -52.99% | +452.08% | +505.07 | 0 Comment | |
| Dudeone | 64.38 | 3/12/2009 |
|
5Y | $4.32 | -58.10% | +422.82% | +480.92 | 0 Comment | |
| e2003 | 91.09 | 3/30/2009 |
|
1Y | $4.75 | -61.89% | +384.51% | +446.41 | 0 Comment | |
| kevleeyang | 70.77 | 1/23/2009 |
|
NS | $7.23 | -74.97% | +369.38% | +444.35 | 0 Comment | |
| js2776 | < 20 | 1/26/2009 |
|
3Y | $8.15 | -77.79% | +364.95% | +442.74 | 2 Comments | |
| yourfavoritepers | 85.49 | 1/26/2009 |
|
3W | $7.47 | -75.77% | +365.45% | +441.22 | 0 Comment | |
| dcfoolz | 72.89 | 1/26/2009 |
|
5Y | $7.47 | -75.77% | +365.45% | +441.22 | 0 Comment | |
| Lafleur526 | 31.50 | 1/26/2009 |
|
3W | $7.47 | -75.77% | +365.45% | +441.22 | 0 Comment | |
| SheepInvstr321 | 96.56 | 1/23/2009 |
|
5Y | $7.36 | -75.41% | +364.67% | +440.08 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
